Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.59
-0.07 (-0.87%)
At close: Apr 28, 2026, 4:00 PM EDT
8.60
+0.01 (0.17%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$640,645
Profits / Employee
-$859,820
Market Cap
193.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 228 | -51 | -18.28% |
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Nkarta | 108 |
| Caribou Biosciences | 97 |
| OmniAb | 89 |
| Cartesian Therapeutics | 75 |
| Korro Bio | 58 |
| Enlivex | 34 |
| Achieve Life Sciences | 28 |
KPTI News
- 7 days ago - Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - PRNewsWire
- 5 weeks ago - Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Benzinga
- 5 weeks ago - Karyopharm Therapeutics Transcript: Study result - Transcripts
- 5 weeks ago - Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - Reuters
- 5 weeks ago - Karyopharm Announces $30 Million Private Placement with RA Capital - PRNewsWire
- 5 weeks ago - Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - PRNewsWire
- 2 months ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Karyopharm Therapeutics Transcript: EGM 2026 - Transcripts